Want to see ATYR full AI Analyst Report?
Top Page
aTyr Pharma
(NASDAQ:ATYR)
Select Model
Select Model
Rating:45Neutral
Price Target:
$5.00
▲(777.19% Upside)
Action:Reiterated
Date:10/30/26
The score is held down primarily by weak financial performance (high losses and ongoing cash burn) and very bearish technical trends (price far below key moving averages with deeply negative momentum). A positive offset comes from FDA alignment on the Phase 3 efzofitimod program, but the stated need for additional capital limits the uplift, and valuation is constrained by a negative P/E and no dividend data.
Positive Factors
FDA-aligned Phase 3 program
FDA agreement on the Phase 3 protocol reduces regulatory uncertainty around efzofitimod’s next clinical step and establishes defined endpoints, enrollment, and timing. If execution is successful, the program could advance a differentiated therapy toward a meaningful unmet medical need.
Negative Factors
Persistent cash burn and funding dependence
Consistently negative operating and free cash flow means aTyr is not self-funding its research and development activities. Continued dependence on financing, partnerships, or other capital sources can constrain strategic choices and expose the company to funding risk while programs advance.
Read all positive and negative factors
Positive Factors
Negative Factors
FDA-aligned Phase 3 program
FDA agreement on the Phase 3 protocol reduces regulatory uncertainty around efzofitimod’s next clinical step and establishes defined endpoints, enrollment, and timing. If execution is successful, the program could advance a differentiated therapy toward a meaningful unmet medical need.
Read all positive factors
aTyr Pharma (ATYR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.42M
Dividend YieldN/A
Average Volume (3M)6.55M
Price to Earnings (P/E)―
Beta (1Y)1.36
Revenue GrowthN/A
EPS Growth21.92%
CountryUS
Employees58
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-24.80
Shares Outstanding98,087,425
10 Day Avg. Volume2,505,615
30 Day Avg. Volume6,550,799
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.08
Price to Sales (P/S)383.20
P/FCF Ratio-1.17
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue64.29
Enterprise Value/Gross Profit-0.54
Enterprise Value/Ebitda-0.20
Forecast
1Y Price Target
$1.00Price Target Upside75.44% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-16.46
Revenue Forecast (FY)N/A
aTyr Pharma Business Overview & Revenue Model
Company Description
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering nov...
aTyr Pharma Earnings Call Summary
Earnings Call Date:Mar 13, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in clinical trials and market opportunities, along with a solid financial position. However, there are challenges related to limited clinical studies for benchmarking and high unmet medical needs in the current market landscape.Positive Updates
Completion of Enrollment in EFZO-FIT Phase 3 Study
aTyr completed enrollment in the global pivotal Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis, enrolling 268 patients across 85 centers in 9 countries.
Negative Updates
Limited Clinical Studies in Sarcoidosis
There are limited clinical studies in sarcoidosis to benchmark against, presenting challenges in pioneering a path forward for measuring improvements in this patient population.
Read all updates
Q4-2024 Updates
Positive
Negative
Completion of Enrollment in EFZO-FIT Phase 3 Study
aTyr completed enrollment in the global pivotal Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis, enrolling 268 patients across 85 centers in 9 countries.
Read all positive updates
Company Guidance
During aTyr Pharma's fourth quarter and full year 2024 conference call, the company provided comprehensive guidance on their clinical developments and strategic outlook. They highlighted the completion of enrollment in the pivotal Phase 3 EFZO-FIT study for efzofitimod, aimed at treating pulmonary sarcoidosis. This trial involves 268 patients across 85 centers in nine countries, testing doses of 3 mg/kg and 5 mg/kg against a placebo over 52 weeks, with a primary endpoint focused on steroid reduction. The company also noted that 75% of diagnosed sarcoidosis patients are prescribed steroids, with the U.S. patient population being 30% larger than previously estimated. Additionally, they have observed four positive data and safety monitoring board reviews with no safety concerns. Financially, aTyr ended 2024 with $75.1 million in cash, supplemented by $18.8 million from an ATM offering. They project their cash runway will last through a year following the Phase 3 readout. The company also discussed plans for commercial readiness and the potential for efzofitimod in a $2-5 billion ILD market, with sarcoidosis representing a significant portion.aTyr Pharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 190.00K | 190.00K | 235.00K | 353.00K | 10.39M | 0.00 |
| Gross Profit | -22.74M | -1.36M | 235.00K | 353.00K | 8.69M | -1.30M |
| EBITDA | -59.80M | -72.56M | -62.48M | -47.66M | -43.65M | -32.47M |
| Net Income | -60.81M | -74.12M | -64.02M | -50.39M | -45.34M | -33.77M |
Balance Sheet | ||||||
| Total Assets | 69.83M | 94.16M | 96.83M | 120.65M | 95.79M | 115.54M |
| Cash, Cash Equivalents and Short-Term Investments | 57.42M | 78.69M | 72.13M | 98.17M | 66.15M | 107.91M |
| Total Debt | 11.30M | 12.03M | 13.28M | 15.10M | 11.53M | 1.38M |
| Total Liabilities | 21.23M | 26.88M | 27.00M | 30.18M | 24.50M | 6.41M |
| Stockholders Equity | 48.79M | 67.48M | 70.02M | 90.66M | 71.46M | 109.30M |
Cash Flow | ||||||
| Free Cash Flow | -54.82M | -62.06M | -69.18M | -37.44M | -43.53M | -33.27M |
| Operating Cash Flow | -54.54M | -61.99M | -69.12M | -33.22M | -41.89M | -33.08M |
| Investing Cash Flow | 22.88M | -5.05M | 17.23M | -20.13M | 47.24M | -91.57M |
| Financing Cash Flow | 29.21M | 66.01M | 39.86M | 66.23M | 5.45M | 110.03M |
aTyr Pharma Technical Analysis
Negative
0.57
Price Trends
13.51
Negative
17.13
Negative
24.31
Negative
Market Momentum
-2.30
Negative
16.44
Positive
31.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATYR, the sentiment is Negative. The current price of 0.57 is below the 20-day moving average (MA) of 7.98, below the 50-day MA of 13.51, and below the 200-day MA of 24.31, indicating a bearish trend. The MACD of -2.30 indicates Negative momentum. The RSI at 16.44 is Positive, neither overbought nor oversold. The STOCH value of 31.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATYR.
aTyr Pharma Risk Analysis
aTyr Pharma disclosed 70 risk factors in its most recent earnings report. aTyr Pharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
aTyr Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $78.72M | -6.27 | -200.67% | ― | ― | -39.90% | |
45 Neutral | $13.42M | -0.22 | -95.59% | ― | ― | 21.92% | |
45 Neutral | $327.19M | -5.19 | -75.35% | ― | 220.34% | 55.73% | |
41 Neutral | $18.53M | -0.42 | -82.06% | ― | ― | -23.49% |
* Healthcare Sector Average
ATYR
aTyr Pharma
5.37
-30.15
-84.88%
XBIT
XBiotech
1.94
-0.46
-19.17%
PRLD
Prelude Therapeutics
4.10
2.53
161.15%
CNTX
Context Therapeutics
0.20
-0.93
-82.21%
OKYO
OKYO Pharma Limited Sponsored ADR
1.50
-1.10
-42.31%
aTyr Pharma Corporate Events
Regulatory Filings and ComplianceShareholder MeetingsStock Split
aTyr Pharma Implements One-for-Forty Reverse Stock Split
Neutral
Oct 27, 2026
On October 27, 2026, aTyr Pharma filed an amendment to its Restated Certificate of Incorporation in Delaware to implement a one-for-forty reverse stock split of its outstanding common shares, effective October 28, 2026. The move, approved by stock...
Shareholder MeetingsStock Split
aTyr Pharma Shareholders Approve Potential Reverse Stock Split
Neutral
Oct 16, 2026
At the October 16, 2026 Special Meeting of Stockholders, aTyr Pharma, Inc. secured shareholder approval for a potential reverse stock split of its common stock. The biotech company, which focuses on therapeutics based on novel biological pathways,...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
aTyr Pharma Aligns with FDA on Efzofitimod Phase 3
Positive
Sep 24, 2026
On September 24, 2026, aTyr Pharma announced it had reached alignment with the U.S. Food and Drug Administration on the protocol for a global Phase 3 trial of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis and restrictive ...
Business Operations and Strategy
aTyr Pharma Regains Global Rights to Efzofitimod
Neutral
Jul 31, 2026
On May 12, 2026, aTyr Pharma received notice from Kyorin Pharmaceutical that it would terminate their collaboration and license agreement covering efzofitimod in Japan, and on July 30, 2026 the parties signed a termination agreement that made the ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.